# Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients

> **NCT06044623** · PHASE3 · RECRUITING · sponsor: **Region Örebro County** · enrollment: 495 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Advanced Breast Cancer
- Quality of Life
- Toxicity
- Older Patients

## Interventions

- **DRUG:** CDK 4/6 inhibitors
- **DRUG:** Endocrine therapy

## Key facts

- **NCT ID:** NCT06044623
- **Lead sponsor:** Region Örebro County
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2028-10-31
- **Final completion:** 2029-05-31
- **Target enrollment:** 495 (ESTIMATED)
- **Last updated:** 2024-11-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06044623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06044623, "Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06044623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*